about
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesLong-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Evaluation of the association between the AC3 genetic polymorphisms and obesity in a Chinese Han population.Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.Genetic variations in the CYP17A1 and NT5C2 genes are associated with a reduction in visceral and subcutaneous fat areas in Japanese women.Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.An 8-wk, randomized, double-blind, placebo-controlled clinical trial for the antidiabetic effects of hydrolyzed ginseng extract.Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulinAllosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).Hypoglycemic effects of aqueous persimmon leaf extract in a murine model of diabetesLiraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study.Nutrition therapy and the management of obesity and diabetes: an update.The safety of thiazolidinediones.Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension.Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?Cardiovascular effects of gliptins.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.Development of RP-HPLC, Stability Indicating Method for Degradation Products of Linagliptin in Presence of Metformin HCl by Applying 2 Level Factorial Design; and Identification of Impurity-VII, VIII and IX and Synthesis of Impurity-VII.The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.Behavioural implications of traditional treatment and closed-loop automated insulin delivery systems in Type 1 diabetes: applying a cognitive restraint theory framework.Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.Assessment of the Therapeutic Potential of Persimmon Leaf Extract on Prediabetic Subjects.Weight Management in Patients with Type 1 Diabetes and Obesity.Optimizing weight control in diabetes: antidiabetic drug selection.Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.High-glycemic index carbohydrates abrogate the antiobesity effect of fish oil in mice.Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way.Nonsurgical diabetes weight management: be prepared for sustainable and practical interventions.Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity.Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.The relationship between the polymorphisms of the CYP17A1 gene and hypertension: A meta-analysis.
P2860
Q24288949-02D14C57-A42B-43CA-98CF-A313476DA75DQ28741419-EC7C3DCA-0140-4FA8-81DC-1B86F7A0E800Q30903369-71BD90DE-F318-433A-826E-EEA5257EFAE9Q33747910-F97FC3FF-37A0-4706-A00A-090BFB097034Q33785136-4CD3E466-F22A-48EC-9F67-B3A2118C1FC0Q34231237-034818D9-D6F0-475F-A32B-4E9825DE79E7Q34379379-74BA44C0-6918-4CDF-BD1C-92CB022CA4F7Q34424578-0850E049-9B4B-46D1-892B-5BC783777C75Q34620604-FA598CDF-EAE0-41E7-928D-18E5B5420D1AQ35454522-096E5D69-3F2D-415E-B119-0F9D90CA6B56Q35673057-BDEC0BD6-E00A-40D8-A6FE-32EC62F8E210Q35727629-8069333A-8414-456F-BDB4-C0E2F16DF131Q35905992-DEF27B96-4E4E-4DDE-B7D0-1AA78A516E90Q37456636-5E7E5A3E-AC13-444D-8D1E-846D88C5B9A6Q37576698-276334BE-281B-4125-8741-185F8A784DADQ37829367-F25E30B6-2D75-468C-B39E-C38488DDC3A6Q37848841-65778A57-7BFF-4925-9CE7-5322D573D363Q37951097-53819A02-ECD2-4041-A2FD-A9B372F77750Q38008005-15F11049-DFA1-42AE-9DDA-C72E68D2872FQ38072259-A7792B33-04CE-4115-A1C0-5114D0B40771Q38113092-1C366893-FAED-4C0C-B7DD-3168F629D80CQ38163071-D9AE2175-CD64-413C-B868-AEBD3C0C032CQ38442816-7BB0F05A-CC3B-41CD-8E26-4652AF75B1F2Q38707307-583F54BC-F29F-4D36-87BA-2C739D827BBEQ39199949-73FFCAF6-E18F-4E00-B5BC-8E2816A642CEQ39381965-D540AE74-A199-4AC3-B64B-991E8FCD9AC1Q39451601-E4F93C2D-2F47-4363-AAC7-79FA1CBF7C99Q41288575-E8C3FACA-CF02-4E0A-BE5B-C1B23A55C65DQ41504692-B6B112C7-4223-4048-AB70-4BEC177C55EFQ41888093-210E4080-56FC-4141-A9CE-2AFD5E838920Q42660412-DB405654-E8DA-4F78-BC18-12CA016DE97EQ42660985-72EDCFBA-DE35-4B2D-8146-6B2CDB1B215CQ46519764-3582C53D-378F-44B4-8BF9-FFDCD078A4D0Q47139736-AD8A4BC0-FBE0-431D-A340-C74B85976C7DQ47396923-694809DD-F8E9-4048-8927-2C1FADDEB18EQ50168195-0F53A1ED-C7D7-4455-AE01-A5852C747168Q51278212-8910A9F8-7F4D-4612-9447-593E19EF8062Q51372081-36909311-D363-459F-BE43-CC3A659E04BAQ53173046-9A0EA78F-A8BE-4ABF-AEB9-BF06DC7ADABB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diabetes medications and body weight.
@en
Diabetes medications and body weight.
@nl
type
label
Diabetes medications and body weight.
@en
Diabetes medications and body weight.
@nl
prefLabel
Diabetes medications and body weight.
@en
Diabetes medications and body weight.
@nl
P2860
P1476
Diabetes medications and body weight.
@en
P2093
Joanna Mitri
Osama Hamdy
P2860
P304
P356
10.1517/14740330903081725
P407
P577
2009-09-01T00:00:00Z